Best Life Sciences Companies in Nevada, United States
The 119 best Life Sciences companies in Nevada, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MMUSA.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Nevada
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MMUSA Online e-commerce platform for fitness supplements | $284M | 235 mo ago | — | Amir Zeibak Founder & CEO | Series D | Top 50M | — | — |
| 2 | Spectrum Pharmaceuticals Developer of small molecule therapeutics for oncology and hematology | $215M | 53 mo ago | 164 164 → 142 (-13%) | — | Acquired | — | 439 patents G‑CSF protein complex therapies for neutropenia and liposomal vincristine chemotherapy delivery | — |
| 3 | JanOne Developer of drugs for treating pain, heart disease, and diabetic neuropathy | $27M | 194 mo ago | 120 | Tony Isaac CEO | Public | — | — | — |
| 4 | Regeneca Manufacturing and marketing a range of branded dietary supplements | $19M | 180 mo ago | — | — | Series A | — | — | — |
| 5 | MegaCare Botanical supplements for medicinal use | $19M | — | — | Syang Su Founder & President | Deadpooled | — | — | — |
| 6 | SonoCine Automated whole breast ultrasound technology for improved breast cancer screening | $15M | 136 mo ago | 1 | — | Series B | — | 28 patents Ultrasound imaging systems for breast and cellular tissue diagnostic screening | — |
| 7 | Emulait Internet first brand offering breastfeeding bottles 40AI top 15%Tech top 29%Growth top 35%Talent top 38% All 12 signals ▾AItop 15% Techtop 29% Growthtop 35% Talenttop 38% Moattop 41% Fundingtop 50% Productbottom 48% Patentsbottom 39% Innovationbottom 30% Globalbottom 29% Marketbottom 25% Customersbottom 6% AI: Holds AI/ML patents (G06N-family CPC) Tech: 46 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 40/100 | $11M | 10 mo ago | 11 | Bob Worrell Co-Founder | Series A | Top 5M | 2 patents Patents concentrated in computing, sensing & instrumentation | — |
| 8 | Research Solutions Provider of AI-powered research workflow solutions, simplifying information access and management for… | $11M | 59 mo ago | 34 | — | Public | Top 5M | — | — |
| 9 | Cyrcadia Health Provider of smart device for breast cancer screening | $9M | 126 mo ago | 3 | — | Series A | — | — | — |
| 10 | United Health Products Provider of a medical device to stop bleeding during surgery | $8M | 45 mo ago | 7 | Brian Thom CEO | Public | — | — | — |
| 11 | Noninvasive Medical Technologies Noninvasive patient monitoring systems | $6M | 201 mo ago | 9 | Ronald McCaughan CEO | Deadpooled | — | — | — |
| 12 | RosVivo Therapeutics Developer of microRNA and small interfering-RNA drugs for multiple indications | $6M | 60 mo ago | 6 | Sandra Poudrier Co-Founder | Series A | — | — | — |
| 13 | DxDiscovery Developing antibody-based diagnostics and therapeutics for infectious diseases | $5M | 13 mo ago | 6 | David AuCoin Co-Founder & Chief Scientific Officer | Funding Raised | — | 4 patents Pertussis diagnostic assays using nucleic acid detection technologies. | — |
| 14 | Strykagen Provider of therapeutics for treating muscle dystrophy | $5M | 33 mo ago | 5 | Dean Burkin Co-Founder & CEO | Funding Raised | — | — | — |
| 15 | BioVie Developer of therapeutics for the treatment of multiple disorders | $4M | 95 mo ago | 18 18 → 20 (+11%) | Terren Peizer Chairman and CEO | Public | Top 50M | 50 patents Pharmaceutical formulations targeting aging, neurodegeneration, and liver disease therapeutics. | — |
| 16 | iDrink Beverages Provider of nano hydration system to deliver nutrients | $3M | 104 mo ago | — | Neil Fineman CEO | Funding Raised | — | — | — |
| 17 | Medical Imaging Corp Online slot gaming platform with maxwin opportunities and deposit options | $2M | 162 mo ago | 40 | Mitchell Geisler CEO | Public | — | 646 patents Developing and producing contrast agents and radiopharmaceuticals for medical imaging | — |
| 18 | Verthermia Provider of a therapeutic platform to treat cancer using hyperthermia | $2M | 65 mo ago | 2 | Mitchel K May CEO | Seed | — | — | — |
| 19 | Heligenics Provider of an assay platform for genetic diagnosis | $1M | 15 mo ago | 5 | Martin Schiller Founder | Series A | — | 23 patents Engineered interferon‑beta cytokine therapeutics and functional genomics screening platforms | — |
| 20 | CareWear Developer of light patch for pain relief and injury recovery for athletes | $1M | 33 mo ago | 4 | Chris Castel Co-Founder & CEO | Seed | Top 50M | 36 patents Phototherapy devices using pulsed blue/purple light for antimicrobial and tissue healing. | — |
| 21 | NexGen Medical System Thrombectomy medical devices for the removal of blood clots | $984K | 95 mo ago | — | George T. Gillies Co-Founder and Advisor | Deadpooled | — | — | — |
| 22 | Isotropic Imaging Innovating breast cancer imaging with dedicated 3D breast CT technology | $865K | 16 mo ago | — | Robert Thast CEO | Public | — | — | 1 partnership · 2 expansions |
| 23 | ActiveO Developer of back pain management therapies | $600K | 190 mo ago | — | — | Deadpooled | — | 21 patents Implantable and injectable devices for precise therapeutic agent delivery into tissue | — |
| 24 | Rollins Medical Soluitons Innovative oxygen mask solutions improving patient safety, efficiency, and cost-effectiveness | $475K | 132 mo ago | 2 | Offord Rollins CEO | Seed | — | — | — |
| 25 | The Orthopaedic Implant Affordable, clinically proven orthopaedic implants improving value for surgeons, hospitals, and patients | $450K | 185 mo ago | 9 | Geoffrey Doyle Co-Founder & Chief Commercial Officer | Acquired | Top 50M | 4 patents Orthopedic implant stabilization systems and surgical clamping devices for bone fixation | — |
| 26 | J&M Urinary Systems Developer of catheters | $392K | 123 mo ago | 3 | Cheryl Mitts Co-Founder | Seed | — | — | — |
| 27 | EnzymeBioSystems Developer of therapies for treating cancer | $390K | 103 mo ago | — | John Harper CEO | Deadpooled | — | — | — |
| 28 | Cell MedX Bio-signal generating device for diabetes therapy and pain management | $348K | 27 mo ago | 1 | — | Public | — | — | — |
| 29 | Imatrex Provider of non-invasive medical imaging devices | $250K | 108 mo ago | 10 | Douglas P Boyd CEO | Seed | — | 22 patents Advanced magnetic beam steering and dose‑optimization for medical X‑ray/therapy systems | — |
| 30 | Zyppah Anti-snoring mouthguard solutions for better sleep and healthier relationships | $185K | 21 mo ago | 5 | Jonathan Greenburg Founder & CEO | Acquired | Top 5M | — | — |
| 31 | GreenBroz Provider of harvesting systems for the cannabis and hemp industry | $150K | 141 mo ago | 38 | Cullen Raichart Founder & CEO | Seed | Top 10M | 5 patents Automated cannabis flower trimming and belt-based bud sorting machinery | — |
| 32 | Rhinal Therapeutics Developer of regenerative therapies for the treatment of diabetes | $20K | 11 mo ago | — | Frank Puglisi Co-Founder | Seed | — | — | — |
| 33 | GBSciences Developer of cannabinoid therapeutics for cardiovascular and other conditions | — | 34 mo ago | 5 | John Poss CEO | Public | — | — | — |
Top 12 Life Sciences companies in Nevada
#1
Series A · Henderson, Nevada · founded 2019 · 11 employees$11Mraised▾
Internet first brand offering breastfeeding bottles. The website provides a starter kit that contains anatomy and classic bottles, nipples, caps, lids, cleaning brushes, and more. The company claims that products are designed on a science-based system that uses 3D scanning, various data, and patented technologies to develop the product. In addition, the website also offers dishwasher baskets.
- Jul 2025Series A$3M
- Mar 2023Series A$11M
#2
Funding Raised · Reno, Nevada · founded 2012 · 6 employees$5.1Mraised▾
Developing antibody-based diagnostics and therapeutics for infectious diseases. This biotechnology research and development firm focuses on creating high-quality, high-affinity antibodies to microbial antigens. These antibodies are used in rapid, point-of-care diagnostics and as prophylactics/therapeutics for infectious diseases. The company's diagnostics portfolio targets diseases where current methods are slow, inaccurate, or impractical. They discover microbial biomarkers, generate monoclonal antibodies, and incorporate them into immunoassay-based diagnostics, emphasizing the lateral flow immunoassay platform. They partner with universities, clinical reference laboratories, and clinical care sites, leveraging their expertise and resources. The company is involved in developing diagnostics for diseases like pertussis, coccidioidomycosis, and others, and is also exploring small molecule-based detection assays. This work has potential social impact by improving disease diagnosis and treatment.
- Apr 2025Grant (prize money)$4.1M
- 2016Grant (prize money)$406.5K
- Jun 2013Grant (prize money)$600K
#3
Series A · Las Vegas, Nevada · founded 2017 · 5 employees$1.2Mraised▾
Heligenics has developed a genetic diagnostic assay for genetic testing. The company's proprietary product includes the in-vitro GigaAssay. It is a gene-screening system that is able to analyze the impact of all potential amino acid substitutions in the functional target protein. It is used for diagnostic purposes.
- Mar 2025Grant (prize money)$398.5K
- Aug 2024Series A$2.6M
- Feb 2023Grant (prize money)$398.5K
- Dec 2020Seed$1.2M
#4
Public · Las Vegas, Nevada · founded 2016$865.2Kraised▾
Innovating breast cancer imaging with dedicated 3D breast CT technology, the company focuses on improving breast cancer detection, especially in women with dense breast tissue. They offer a dedicated breast CT platform providing true 3D imaging without compression, boasting high spatial resolution. The company is preparing for a pivotal clinical study, aiming to establish its technology as a leader in breast imaging. The company operates in the global breast imaging market, driven by the demand for earlier and more accurate cancer detection. The company utilizes advanced technology and a focused clinical strategy, offering a unique opportunity to invest in a fast-growing sector. The company is involved in medical imaging, clinical research, and commercialization, advancing its technology from proven science to real-world impact.
- Feb 2025Post IPO$320.8K
- Sep 2023Post IPO$523.4K
- Nov 2020Post IPO$20.9K
#5
Acquired · Henderson, Nevada · founded 1987 · 164 employees$214.5Mraised▾
Developer of small molecule therapeutics for oncology and hematology. The company's product line includes 'Rolvedon' for non-myeloid malignancies and Poziotinib an orally administered, irreversible tyrosine kinase inhibitor (TKI) for the treatment of solid tumors.
- Jan 2022Post IPO$20M
- Apr 2016Post IPO$3M
- Jul 2013Post IPO$27.5M
- Nov 2010Grant (prize money)$977.9K
#6
Seed · Las Vegas, Nevada · founded 2023$20Kraised▾
Developer of regenerative therapies for the treatment of diabetes. It offers a patented intranasal powder GLP-1 t3 treatment for compliance and adherence for pediatrics.
- Jul 2025Seed$20K
#7
Acquired · Las Vegas, Nevada · founded 2012 · 5 employees$185Kraised▾
Anti-snoring mouthguard solutions for better sleep and healthier relationships. They offer clinically proven, dual-action technology designed to stop snoring by addressing its root cause: the tongue. Their product gently holds the tongue in place, preventing airway blockage. They provide a custom comfort fit through a simple customization process. They offer a risk-free trial with a full refund guarantee. Their solutions are biomechanically engineered and backed by a scientific advisory board. They also support Breast Cancer Awareness with a portion of proceeds from specific products donated to the Susan G. Komen Foundation. They offer products like mouth tape and nasal strips. The website offers features like cart, login, shop now, science, reviews, search, and subscription.
- Aug 2024Seed$60K
- Apr 2023Seed$125K
#8
Funding Raised · Reno, Nevada · founded 2013 · 5 employees$4.9Mraised▾
Strykagen provides therapeutics for treating muscle dystrophin. The product Stryka-pro1 is a small extracellular matrix protein, the product helps in increasing α7β1 integrin and utrophin in the patient muscle cells.
- Sep 2023Grant (prize money)$959K
- Apr 2015Grant (prize money)$3.7M
- Sep 2014Grant (prize money)$225K
#9
Series D · Carson City, Nevada · founded 1995$283.8Mraised▾
Online e-commerce platform for fitness supplements. The company offers several nutritional products such as bodybuilding products, sports, protein, weight management, brain health, sexual health, women's health, and joint health. The company has a portfolio of around 60 products, a few of which include creational serum, Aero rider pre, Super green serum, Uplift, Brainstorm, etc.
- Nov 2006Series D$283.8M
#10
Public · Mesquite, Nevada · founded 1997 · 7 employees$7.9Mraised▾
Provider of a medical device to stop bleeding during surgery. It offers a HemoStyp, a bio-compatible sterile gauze that produces hemostasis when applied to a cut or open wound to help control bleeding.
- Sep 2022Post IPO$7.6M
- Jul 2016Post IPO$56.7K
- Oct 2014Post IPO$168K
- Jun 2010Post IPO$25K
#11
Public · Henderson, Nevada · founded 2006 · 34 employees$11Mraised▾
Research Solutions is a vertical SaaS and AI company specializing in simplifying research workflows for academic institutions, life science companies, and other organizations. Its solutions cater to article management, citation tracking, and knowledge management needs.
- Jul 2021Grant (prize money)$59K
- Feb 2017Grant (prize money)$33.2K
- Jun 2016Post IPO$5.2M
- Feb 2015Grant (prize money)$17K
#12
Public · Carson City, Nevada · founded 2014 · 1 employees$348Kraised▾
Cell MedX Corp discovers and develops therapeutic products for patients with diseases such as diabetes. The company aims to offer alternatives to conventional therapies in the management of pain and chronic disease. The company's eBalance is a biosignal generating device, used both as a professional clinic-based as well as a home use device. The device is undergoing both pre-clinical and clinical trials as of June 2017. The indications of use for the device - reducing average blood sugar (HbA1c), improving diabetic neuropathy and foot pain, regulating blood pressure, improving kidney function, healing non-healing wounds.
- Mar 2024Post IPO$45K
- Nov 2020Post IPO$82K
- May 2020Post IPO$26K
- Nov 2014Post IPO$195K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.